There are healthcare companies that chase attention, and then there are companies that chase outcomes. Carna Health never looked for the spotlight. It looked for the disease. Founded in Boston in...
There are healthcare companies that chase attention, and then there are companies that chase outcomes. Carna Health never looked for the spotlight. It looked for the disease. Founded in Boston in April 2021, Carna Health built itself around a global truth most systems prefer not to sit with: chronic kidney disease does not wait for modern infrastructure, and it does not care about borders. Affecting 1 in 10 adults worldwide and projected to become the 5th leading cause of death by 2040, CKD is not a specialty problem. It is a population problem hiding in plain sight.
That mindset starts with Salvatore G. Viscomi, MD, Co-Founder and CEO. Fourteen years at Harvard Medical School and Brigham and Women’s Hospital will sharpen anyone’s clinical instincts, but co-founding Brigham NightWatch, the world’s first academic teleradiology network, sharpened something else: scale. Prevention was never theoretical for Salvatore G. Viscomi, MD. It was always operational. Alongside Boris Berat, Co-Founder and Chief Technology and Product Officer and founder of BrightMarbles Group, Carna Health launched internationally first. Bermuda came before buzz. Africa and Asia came before applause. That was not accidental. It was the thesis.
That thesis just got more oxygen. Carna Health closed an $8M capital raise, bringing total funding to $11.4M following a $3.4M venture round in February 2025. The round includes participation from Dr. Jay Rosan, Cenk Bekmezçi, Jose Pereyra, Mark Boulding, Brandon Salomon, Andrew Roosevelt, Jeff Lindsey, Joseph White, John Brooks, Elvis Ndansi, and Dr. Salvatore Viscomi. No valuation theatrics. No noise. Just capital aligned with execution.
The platform does the talking. Carna Health integrates point-of-care diagnostics with AI-driven analytics to screen, monitor, and manage CKD through a Cardio-Kidney-Metabolic lens. In Cameroon, a pilot screened 550+ participants in three days. Nineteen percent showed markers consistent with CKD stages 3 to 5. More than 50% required follow-up. When that math stretches across the 35,000 individuals already screened in Cameroon, the signal gets uncomfortably clear.
Partnerships here are functional, not decorative. A strategic agreement with Siemens Healthineers connects Carna Health’s digital platform with global point-of-care diagnostics. Nova Biomedical supports testing infrastructure on the ground. Active programs now span Bermuda, Cameroon, the Philippines, and the Dominican Republic, with expansion planned into the U.S. and Turkey. The stated goal is 25M people screened globally by 2030, which sounds ambitious until you realize how fast unmet need compounds.
This is a B2G model built for real-world friction, led by operators who know how to move across systems and cultures. Mary Miller Sallah runs operations as COO. Tom Dolan stewards capital as CFO. Elvis Ndansi leads population health. John L. Brooks drives strategy. The kidney may be small. The implications of getting this right are not.
